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ABSTRACT 
Periodontitis (PD) is a chronic inflammatory disease characterized by destruction of the tooth 
supporting tissues; gingiva, periodontal ligament, and alveolar bone. Myeloid cells, including 
monocytes and macrophages, play a crucial part in the inflammatory host response by clearing 
pathogens and producing a vast array of inflammatory mediators. However, during chronic 
inflammation, the actions of these cells can contribute to tissue degradation. By utilizing 
clinical samples and different cell culture systems, this thesis aimed to investigate the role of 
monocytes and macrophages, along with factors that regulate them in PD.  
In study I, we found elevated gene and protein expression of MMP-12 in PD gingival tissue 
and the expression was mainly attributed to CD68+CD64+CD14+ monocyte-derived cells. 
These cells displayed low expression of the co-stimulatory molecule CD200R. Induced 
inflammation in oral tissue cultures reduced the CD200R and increased the MMP-12 
expression in monocyte-derived cells. CSF-2 was found to potently induce MMP-12 and a 
CD200 ligand reduced MMP-12 production in monocyte-derived cells, suggesting that the 
CD200/CD200R pathway is a potential target to modulate harmful inflammatory processes in 
PD. 
In study II, the expression of S100A12 was found to be high in monocytes, decreased during 
macrophage differentiation, and unaltered upon macrophage polarization. Analysis of 
S100A12 in different monocyte subsets revealed that classical monocytes had the highest 
expression followed by the intermediate and non-classical subsets. Peripheral blood monocytes 
from PD patients were more frequently positive for S100A12 and showed higher secretion in 
vitro compared with controls. The importance of monocytes for S100A12 production was 
demonstrated in oral tissue cultures. The protein expression of S100A12 was increased in 
gingival tissue along with higher frequencies of S100A12+ monocyte-derived cells. S100A12 
levels in saliva reflected the severity of PD, suggesting A100A12 as a potential biomarker for 
disease. 
The expression of the macrophage growth factors CSF-1 and IL-34 in gingival tissue and 
gingival fibroblasts (GFs) was investigated in study III. Elevated CSF-1 protein expression 
was found in gingival tissue from PD patients while the levels of IL-34 were similar in PD and 
control tissue. CSF-1 and IL-34 were expressed and produced by GFs constitutively and pro-
inflammatory stimuli induced their secretion. CSF-1 and IL-34 secretion did not differ in GFs 
isolated from PD patients compared with controls in unstimulated condition or in response to 
TNF-α or IL-1β stimuli. 
In study IV, we found elevated expression of CSF-1R in gingiva from PD patients. HLA-
DR+CD64+ macrophages displayed similar frequencies in PD and controls with no difference 
regarding CSF-1R expression. In peripheral blood mononuclear cells, CSF-1R inhibition did 
not alter the monocyte subsets or the expression of the myeloid markers CD64, CD206 or 
CD163. However, CSF-1R blockade attenuated MMP production in PD gingival explants. 
Thus, CSF-1R may contribute to the inflammatory processes leading to tissue degradation in 
PD.   
In summary, these studies investigated the involvement of monocytes and macrophages in PD 
as well as the expression of factors that regulate their functions. Furthermore, strategies to 
target tissue-destructive myeloid cell related processes were explored.    
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1 INTRODUCTION 
 
1.1 INNATE IMMUNITY OF THE ORAL MUCOSA 
The oral mucosa is constantly challenged with a particularly diverse microbiota. To prevent 
colonization of the periodontal tissues, the immune system needs to eliminate infectious 
pathogens, and at the same time keep the commensal microbiota in balance. The first line of 
defense is comprised of physical and chemical barriers, complement system, and innate 
myeloid and lymphoid cells. In the oral cavity, the constant flow of saliva and gingival 
crevicular fluid (GCF) disturbs the colonization of microbial biofilms. These fluids exhibit 
antimicrobial properties through enzymes, immunoglobulins, complement system factors, and 
leukocytes. Tissue resident cells e.g. epithelial cells and fibroblasts provide the structure and 
integrity of the mucosal barrier. Epithelial cells form the outer layer of the mucosa and are 
connected to each other through intercellular junctions. Aside from forming a physical barrier, 
epithelial cells recognize pathogen associated molecular patterns (PAMPs) through pattern 
recognition receptors (PRRs). Fibroblasts are the most numerous cell type in the connective 
tissue and are important regulators of the extracellular matrix. In response to bacterial insults, 
epithelial cells and fibroblasts produce antimicrobial peptides and inflammatory mediators that 
attract and activate immune cells. Innate immune cells, including monocytes, macrophages and 
dendritic cells (DCs) are situated within the mucosal barrier and play an important role as 
scavengers. These cells are also equipped with PRRs and play an important part in clearing 
pathogens that have breached the epithelium. Innate immune cells exert several functions to 
eliminate the pathogens, including phagocytosis and production of antimicrobial peptides and 
inflammatory mediators that eliminate bacteria and attract more leukocytes to the site of 
infection. Furthermore, they also take part in activation of the adaptive immune response by 
engulfing and processing pathogens for presentation to T-lymphocytes. Proinflammatory 
mediators produced by innate immune cells in response to infectious stimuli, may in a chronic 
inflammatory setting lead to detrimental effects on host tissues1,2. 
 
1.2 PERIODONTITIS (PD) 
Inflammatory diseases of the periodontium are common conditions. Plaque-induced gingivitis 
is initiated by the microbiota and confined to the soft tissues. It is diagnosed by bleeding on 
probing (BOP) assessed as the proportion of bleeding sites and can be reversed by removing 
the dental plaque3. However, if the microbial biofilm remains, gingivitis may advance into 
periodontitis (PD) in susceptible individuals4. The chronic inflammatory disease PD is 
characterized by irreversible destruction of the tooth supporting tissues; e.g. gingiva, 
periodontal ligament, and alveolar bone. If left untreated, the chronic inflammation eventually 
results in tooth mobility and tooth loss4. The prevalence of PD is high with approximately 29% 
of individuals aged 20-80 years in Jönköping, Sweden, reported to be affected by a moderate 
form of the disease, and 11% with severe disease5. The global prevalence of severe PD has 
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been reported to be 11.2%6. The quality of life is negatively impacted by PD due to 
compromised tooth function and aesthetics7, and PD may also be a risk factor for general health 
by impacting the onset and severity of systemic diseases, e.g. cardiovascular disease and 
diabetes8.  
The diagnosis of PD is based on several parameters: measurement of BOP, probing depth, 
clinical attachment loss (CAL), and radiographic bone loss. In the 1999 classification of PD, 
the extent of disease was characterized as local if ≤ 30% of sites were involved and generalized 
if ≥ 30% of sites were involved. Severity of disease was based on CAL and classified as slight, 
moderate and severe (advanced)9. A new classification system was presented in 2017, 
classifying PD in stages (I-IV) defined by severity, complexity, and extent and distribution. 
The progression and prognosis are determined by grades (A-C) as defined by evidence of, or 
risk for rapid progression, anticipated treatment response, and effects on systemic health10. The 
treatment of PD includes motivating the patient to remove supragingival plaque by maintaining 
oral hygiene procedures, as well as non-surgical and surgical debridement followed by 
supportive periodontal care11.  
 
1.2.1 The periodontium 
The periodontium is comprised of the tissues that surround and support the teeth. These include 
the root cementum, periodontal ligament, gingiva, and alveolar bone. The root cementum is a 
hard, avascular structure covering the roots, and its main function is to anchor the periodontal 
ligament fibers to the teeth. The alveolar process is the bone that forms the sockets housing the 
teeth, and the specialized connective tissue located between the root cementum and the alveolar 
bone makes up the periodontal ligament. It consists of a diverse cell population as well as 
collagen fiber bundles anchored to the teeth and the bone, providing support during forces of 
mastication12. The gingiva covers the alveolar bone and surrounds the teeth and is comprised 
of epithelium and underlying connective tissue. The epithelium is divided into three different 
types based on location and function; the gingival epithelium, sulcular epithelium (SE), and the 
junctional epithelium (JE). The gingival epithelium extends from the muco-gingival junction 
to the gingival crest. The SE is in contact with the tooth without being attached, forming the 
gingival sulcus, or gingival crevice. The SE merges with the JE which is attached to the tooth 
surface (Figure 1). The highly vascularized connective tissue adjacent to the JE provides a 
constant infiltration of leukocytes, both during homeostasis and disease12.  
The dento-gingival junction may be the most vulnerable part of the periodontium, constituting 
the border between the periodontal tissues and the oral cavity. The highly specialized JE is of 
great importance as it is attached to the tooth and forms a protective barrier against bacteria in 
the sulcus13. The high permeability due to its wide, fluid-filled intercellular spaces allows for 
infiltration of leukocytes and release of antimicrobial molecules into the sulcus and oral cavity 
with the GCF13,14. The composition of immune cells in healthy gingiva is primarily constituted 
by a rich T cell and neutrophil infiltrate along with monocytes, and macrophages15-17. During 
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homeostasis, this defense system keeps the commensal microbiota in balance with the host and 
prevents colonization of the periodontal tissues. 
 
 
  
 
 
Figure 1. Schematic illustration of the periodontium. The sulcular epithelium (SE) merges with the junctional 
epithelium (JE) which is attached to the tooth surface. The space between the sulcular epithelium and the tooth is 
called the gingival sulcus, or gingival crevice and holds the gingival crevicular fluid (GCF). The periodontal 
ligament is attached to the root cementum and the alveolar bone and provides support during mastication. 
Illustration by Julia Landmark Clark. 
 
1.2.2 Pathogenesis of PD 
The formation of a pathological periodontal pocket is characterized by apical migration of the 
JE, converting to pocket epithelium. Pathological pockets are likely formed due to intra-
epithelial cleavage caused by migration of leukocytes and direct interaction with bacterial 
products, followed by degradation of the connective tissue apically to the JE13. Recently 
acquired knowledge suggests that this is due to a disrupted balance between the host and the 
commensal microbiota. Keystone pathobionts such as Porphyromonas gingivalis subvert the 
immune response and impairs innate immunity. The host-mediated immunopathology that 
ensues leads to tissue degradation which provides a recess for colonization. The inflammation 
causes release of nutritional factors favoring pathobionts resulting in a shift in microbial 
composition18,19. Thus, microbial insult initiates the inflammation, but the development and 
progression of PD is considered to be mediated by a dysregulated immune response. Several 
risk factors are known to affect the onset and progression of disease, e.g. immunodeficiency, 
systemic disease, smoking, stress, diet and genetic risk factors4 (Figure 2). 
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Figure 2. Schematic illustration of the pathogenesis of PD. Adapted from Page and Kornman 199720. The 
pathogenesis of PD is multifactorial and involves dysbiosis, genetic and environmental risk factors, and a 
dysregulated immune response. Abbreviations: LPS; lipopolysaccharide, PMN; polymorphonuclear leukocytes, 
MMPs; matrix metalloproteinases. 
 
The histopathological changes in the gingiva during the progression of PD were originally 
described in four stages by Page and Schroeder including the initial lesion dominated by 
neutrophils, the early lesion displaying large numbers of T-cells and macrophages, and lastly 
the established and advanced lesions, dominated by plasma cells21.  
In the initiating step, toxins released by bacteria stimulate epithelial cells, gingival fibroblasts 
(GFs) and macrophages to produce a vast array of cytokines and chemokines. These events 
lead to the upregulation of adhesion molecules on endothelial cells, increased vascular 
permeability, and recruitment of leukocytes to the site of infection22. Among the first 
responders are neutrophils, migrating into the tissue over a chemoattractant gradient. They 
combat the bacterial insult by utilizing phagocytosis and microbicidal functions, including the 
release of reactive oxygen species and antimicrobial peptides. Aside from killing bacteria, 
neutrophil-activity also causes connective tissue degradation through production matrix 
metalloproteinases (MMPs)23. As the inflammation ensues, more leukocytes are attracted. 
Lymphocytes, monocytes and macrophages also accumulate in the tissue at this stage of the 
disease22. In the enhanced inflammatory environment, the production of cytokines and 
proteolytic enzymes is maintained, leading to deepened periodontal pockets due to the 
degradation of the connective tissue and formation of the apically proliferating pocket 
epithelium. In the established periodontal lesion, B-cells and antibody producing plasma cells 
can be observed in great numbers in the affected connective tissue. As the lesion progresses, 
osteoclast precursors are accumulated and differentiate into bone resorbing osteoclasts22. 
Although the histopathological changes during progression of PD have been extensively 
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studied, it is still unclear what changes in the cellular composition causes the inflammation to 
“tip over” and become destructive. Previous studies have reported that increasing numbers of 
B cells characterizes PD lesions compared with gingivitis24,25. Further, when comparing the 
cellular infiltrate of PD and gingivitis, Thorbert Mros et al. found that PD lesions contained 
larger numbers of macrophages, plasma cells, as well as B cells expressing cluster of 
differentiation (CD) 526. By utilizing multi-color flow cytometry, more in-depth analysis of 
different immune cell populations in gingiva can be performed, and possibly link certain 
phenotypes to disease development and progression. For example, Dutzan et al. analyzed the 
frequency of different immune cell populations in PD and healthy gingiva and found similar 
frequencies of T-cells, B-cells and DC-Mac (dendritic cells, monocytes, macrophages), but an 
increased proportion of granulocytes in PD15. With the notion that interleukin (IL)-17 is a key 
mediator of inflammatory bone loss and associated with accumulation of neutrophils in animal 
models of PD, the IL-17 expressing cells were characterized. The authors found that IL-17 
expression is mainly attributed to CD4+ T cells and that the percentage of this population 
producing IL-17 is increased in PD15. Thus, identifying specific immune cell phenotypes and 
their functions is important in order to understand the events that lead to initiation and 
progression of PD. 
 
1.3 INFLAMMATORY MEDIATORS IN PD 
During the complex inflammatory processes of PD, leukocytes and tissue resident cells interact 
with each other to orchestrate the host response against the microbiota. The secretion of a vast 
number of inflammatory mediators is induced by bacterial products such as 
lipopolysaccharides (LPS) binding to toll-like receptors (TLRs) on host cells27,28. Expression 
of several cytokines involved in regulating inflammatory processes has been found to be 
elevated in gingival tissue and GCF from PD-affected sites, including tumor necrosis factor-α 
(TNF-α), IL-1β, IL-6, IL-10, and receptor activator of nuclear factor kappa-B ligand 
(RANKL)29-34. TNF-α and IL-1β are produced by many different cell types, and especially by 
monocytes and macrophages. They are key pro-inflammatory cytokines with wide biological 
effects, including regulation of cytokines, chemokines, growth factors, and proteolytic 
enzymes35. Studies in animal models of PD have demonstrated that targeting TNF-α and IL-1β 
reduces inflammatory mediator production, leukocyte recruitment, and alveolar bone 
resorption36-38. In humans, targeting TNF-α is an established treatment for several chronic 
inflammatory diseases such as rheumatoid arthritis (RA), and it has been shown to have a 
positive effect on periodontal parameters in RA patients with PD39-42. Another pleiotropic 
cytokine is IL-6 which plays an important role in acute-phase responses, hematopoiesis and 
immune reactions43. It is believed to have an important function in the initiation of PD, but also 
takes part in osteoclast differentiation and stimulates production of inflammatory mediators by 
gingival cells44-46. The anti-inflammatory cytokine IL-10 is crucial for the regulation of the 
immune response and limiting tissue damage47. In experimental PD, IL-10 deficient mice 
exhibit accelerated alveolar bone resorption, demonstrating its tissue protective role during 
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periodontal inflammation48. Chemokines are a large family of cytokines that regulate the 
migration of immune cells to the site of infection or injury49. The chemokines C-C motif 
chemokine ligand (CCL) 2 and IL-8 are crucial for the recruitment of monocytes and 
neutrophils respectively and are increased in gingival tissue during PD50,51.  
MMPs are a family of proteolytic enzymes that play important roles in tissue modulation by 
orchestrating extracellular matrix turnover. They also take part in modulating the immune 
response by cleaving cytokines and chemokines52. MMP activity is controlled by endogenous 
tissue inhibitors of metalloproteinases (TIMPs), and an imbalance between MMP and TIMP 
production may have consequences for periodontal tissue integrity during PD53. MMPs are 
divided into different subclasses based on their structure and target substrate. Among them are 
MMP-1, -8, and 13 (collagenases), MMP-2 and -9 (gelatinases), MMP-3 and -10 
(stromelysins), and MMP-7 and -26 (matrilysins). These MMPs degrade various matrix 
components such as collagen, gelatin, fibronectin, and elastin54. Another MMP not belonging 
to these groups is MMP-12, or macrophage metalloelastase, which is produced my monocytes 
and macrophages and targets elastin and its precursor tropoelastin55,56. Elevated expression of 
several MMPs have been reported in gingival tissue, GCF, and saliva during PD57-59, and their 
involvement in inflammatory destructive processes has been demonstrated in animal models. 
Ramamurthy and colleagues utilized a rat model of PD and reported decreased MMP activity 
and cytokine levels in the gingival tissue, as well as reduced alveolar bone loss following 
administration of MMP inhibitors60. Furthermore, in humans, a low dose of doxycycline has 
been shown to have tissue protective effects by inhibiting MMP activity61. Macrophages 
produce MMPs abundantly in response to proinflammatory stimuli which may contribute to 
tissue destruction during chronic inflammation62.  
The S100 protein family consists of 25 proteins involved in a wide range of cellular processes 
including proliferation, differentiation, migration and inflammation63. S100A12 is a protein 
that belongs to a subgroup of this family termed calgranulins, and induces cellular activation 
and production of proinflammatory cytokines by binding to receptor for advanced glycation 
end-products and TLR464,65. It is also a potent chemoattractant for monocytes and neutrophils66. 
S100A12 is elevated in inflammatory diseases such as RA67, and its levels in saliva has been 
shown to correlate with gingival inflammation68.    
The colony stimulating factors (CSFs) CSF-1, IL-34, and CSF-2 are crucial for the 
differentiation, proliferation and survival of monocytes, macrophages, and dendritic cells 
(DCs)69. However, if overexpressed, they can contribute to harmful inflammatory processes70. 
Studies have investigated the expression of these growth factors in oral fluids to assess their 
potential involvement in PD. Previous studies from our group demonstrated increased CSF-1 
levels and decreased IL-34 in saliva from PD patients71,72. Elevated CSF-2 levels have been 
reported in GCF from PD patients, along with increased gene expression levels in gingival 
tissue73.  
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1.4 THE ROLE OF FIBROBLASTS IN PD 
GFs are the most abundant cells in the gingiva and play an important role in producing and 
remodeling the collagenous extracellular matrix. They actively take part in the host response 
by responding to bacterial products through TLRs and sustain inflammation by exhibiting LPS 
tolerance74,75. Moreover, GFs can also target bacteria directly by producing antimicrobial 
peptides76. In response to inflammatory stimuli in vitro, and in co-cultures with peripheral 
blood mononuclear cells (PBMCs), fibroblasts from the periodontal tissues display elevated 
expression of the osteoclastogenic factors CSF-1, IL-34, RANKL, TNF-α, and IL-1β, and 
contain the capacity to induce osteoclast formation77-80. Co-culture experiments have also 
demonstrated that GFs are important for the retention, survival and proliferation of both 
lymphocyte and monocyte populations80.  
Exposure to inflammatory mediators may result in epigenetic alterations with changes in gene 
activation and cell phenotype as a result81. Fibroblasts display great plasticity and can undergo 
phenotypic changes in response to different stimulations in vitro82,83. In line with this, a number 
of studies have reported altered characteristics of fibroblasts isolated from PD-affected 
periodontal tissues. Periodontal ligament fibroblasts (PDLFs) from PD patients have been 
reported to exhibit an enhanced gene expression of several inflammatory mediators including 
IL-6, and sustain their inflammatory profile when isolated and cultured in vitro without 
bacterial stimuli84. In another study, Sokos et al. reported that P. gingivalis induces genes 
related to osteoclastogenesis in PDLFs85. Moreover, the authors found that in co-cultures of 
PDLFs from control subjects and PBMCs, osteoclast differentiation was decreased after P. 
gingivalis challenge. However this was not observed in cultures with PDLFs from PD patients, 
likely caused by desensitization to P.gingivalis. In another study, GFs isolated from inflamed 
gingiva were shown to quickly upregulate a high expression of the proinflammatory cytokines 
IL-6, IL-8, IL-1β, and TNF-α in response to P. gingivalis LPS compared to GFs from 
controls86.  On the other hand, a compromised immune response in GFs isolated from inflamed 
gingiva has also been reported, with lower IL-6 production87. Taken together, the immune 
regulatory functions of GFs and their possible altered inflammatory characteristics in inflamed 
gingiva marks them as interesting targets for investigation in PD.  
 
1.5 MONOCYTES 
Monocytes belong to the mononuclear phagocyte system together with macrophages and 
conventional DCs. They derive from hematopoietic stem cells in the bone marrow and go 
through a series of differentiation stages during their development:  a common myeloid 
progenitor (CMP), a granulocyte-macrophage progenitor (GMP),  a common macrophage  and 
DC precursor (MDP), and lastly a committed monocyte progenitor (cMoP)88-90.  
After development, monocytes are released into circulation where they make up approximately 
10% of the leukocyte population. They are key effector cells during inflammation by exerting 
microbicidal functions, but also take part in tissue remodeling91. Three monocyte subsets have 
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been identified based on the differential cell surface expression of the LPS co-receptor CD14 
and the Fc gamma receptor IIIa (CD16). Classical monocytes (CD14++CD16-) are the most 
numerous in the peripheral circulation making up 80-90% of the monocyte population and stay 
in the blood stream for approximately one day. Intermediate monocytes (CD14+CD16+) and 
non-classical monocytes (CD14+CD16++) constitute the remaining 10-20% and remain in 
circulation for approximately 4 and 7 days respectively92,93. Recent evidence from gene 
expression profiling and fate-mapping studies suggests that the intermediate and non-classical 
subsets are derived from classical monocytes that undergo differentiation and transformation 
in the blood stream, and thus are not derived from the bone marrow like classical monocytes93-
95.   
 
 
Figure 3. The development of monocytes and macrophages starts in the bone marrow. A common myeloid 
progenitor gives rise to a granulocyte-macrophage progenitor (GMP). The GMP differentiates into a macrophage 
and DC precursor (MDP), which in turn differentiates into a committed monocyte progenitor (cMoP). Classical 
monocytes are differentiated from the cMoP and released into the blood stream and further differentiate into 
intermediate and non-classical monocytes. Classical monocytes are also recruited to the tissues and take on the 
role as effector monocytes or differentiate into monocyte-derived macrophages or DCs. Illustration by Reuben 
Clark.   
 
The monocyte subsets exhibit some distinct features, although varying results have been 
reported regarding their functions and gene expression. The classical monocyte population has 
been reported to express high levels of chemokine receptors such as CCR1, CCR2, and C-X-
C chemokine receptor (CXCR) 1 which enables them to quickly respond to infection or injury 
and migrate into the tissue over chemokine gradients95,96. This subpopulation also expresses 
high levels of PRRs and secretes pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 
when stimulated with PRR-agonists97. Classical monocytes possess high potential for 
phagocytosis98,99, as well as antimicrobial activity by producing myeloperoxidase, lysozymes, 
and S100 proteins100. They have been shown to express lower levels of antigen-presenting 
molecules than the other subsets but strongly upregulate the expression of MHC class II 
molecules in response to inflammatory stimuli101. Their antigen-presentation ability has further 
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been demonstrated in mice, showing their ability to take up antigens, and recirculate to the 
lymph nodes102. 
In a study by Wong and colleagues it was reported that intermediate monocytes express a 
majority of genes and surface proteins at levels between the classical and non-classical 
subsets95. However this subset stands out with a high constitutive expression of MHC II, and 
thus likely plays an important role in antigen-presentation101. Other  markers that stand out are 
CCR5 and TNF receptors, suggesting that they are highly responsive to chemokine and 
cytokine signaling103. Intermediate monocytes also exhibit high expression levels of pro-
inflammatory mediators such as IL1β, IL-12, IL-18, IL-23, cathepsins and MMPs104, and are 
sometimes referred to as “inflammatory monocytes” due to their expansion in the circulation 
in several inflammatory diseases105-107.  
The non-classical subset patrols the blood vessels for pathogens or tissue damage and takes 
part in wound healing processes108,109. This patrolling behavior has been shown to be dependent 
on lymphocyte function-associated antigen 1 and the chemokine receptor CX3CR1
108. Non-
classical monocytes express lower levels of proinflammatory cytokines in response to TLR-
agonists compared with the other subsets and exhibits low expression of genes related to 
bacterial phagocytosis97,104. On the other hand, this subset expresses high levels of the 
complement component C1QA and CD16A which are involved in antibody mediated 
phagocytosis104. Another feature that stands out with the non-classical monocytes is their role 
in the inflammatory response against viruses and nucleic acids, which is mediated via TLR7 
and TLR898.  
The intermediate and non-classical monocyte subsets express high levels of CSF-1R compared 
with classical monocytes and are highly dependent on CSF-1R signaling for their survival and 
maintenance, which is evident by the reduction of these subsets in RA patients treated with a 
monoclonal antibody against CSF-1110.  
 
1.6 MACROPHAGES 
Macrophages are distributed throughout the tissues, and for a long time it was believed that 
they derive solely from circulating blood monocytes111. However, studies have shown that 
tissue-resident macrophages in many tissues-compartments throughout the body are seeded 
prior to birth and maintain themselves without replenishment from blood monocytes94,112. 
During infection, tissue resident macrophages are supplemented by classical monocytes, which 
migrate in large numbers into the tissue and take on the role as effector 
monocytes/inflammatory macrophages. These cells produce high levels of TNF-α and 
inducible nitric oxide synthase (iNOS) and are crucial players in the clearance of pathogens 
and orchestrating the immune response. The fate of monocytes is highly dependent on the tissue 
environment, and they may also differentiate into monocyte-derived DCs or a macrophage 
phenotype involved in efferocytosis and tissue healing113. 
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Regardless of origin, macrophages display great plasticity and undergo polarization in response 
to different environmental cues. They are generally categorized into two different subtypes: 
classically activated/M1 and alternatively activated/M2 macrophages. Classically activated 
macrophages possess crucial antimicrobial properties. They induce and sustain inflammation 
which in the long run can have harmful effects on host tissues. Alternatively activated 
macrophages are known as anti-inflammatory and play a key role in phagocytosis, immune 
regulation, and tissue remodeling114 (Figure 4).  
 
Figure 4. Macrophages are plastic cells that undergo polarization in response to environmental cues. They exert a 
wide array of functions in inflammation and homeostasis. Illustration by Reuben Clark. 
 
The concept of M1/M2 macrophages stems from the Th1/Th2 polarization of T cells, where 
IFN-γ producing Th1 cells and IL-4 producing Th2 cells were shown to activate different 
effector functions in macrophages115. Macrophages are commonly polarized into an M1 
phenotype with LPS/ IFN-γ and M2 with the Th2 cytokines IL-4/IL13 in vitro116. Macrophage 
polarization has also been shown to be impacted by the differentiation stimuli, where CSF-1 
and CSF-2 induce anti-inflammatory and proinflammatory features respectively116. Among the 
markers upregulated during M1 polarization are the co-stimulatory molecules CD64, CD80, 
CD86, and CD40116,117. The M1 phenotype produces pro-inflammatory cytokines such as TNF-
α, IL-1β and IL-6116,118. Apart from IL-4/IL-13, additional stimulus inducing M2 polarization 
has been found, inducing different gene expression profiles. This has led to further subgrouping 
of the alternatively activated macrophages into M2a, M2b, and M2c119. M2 polarized 
macrophages express high levels of the scavenger receptors CD206 and CD163116, as well as 
the co-inhibitory molecule CD200R, which is an important regulator of the immune response 
through ligation with CD200120,121. More specifically, in terms of the M2a, M2b, M2c concept, 
in vitro studies have demonstrated that CD206 and CD200R expression is up-regulated on M2a 
macrophages polarized with IL-4/IL-13120. Induction of the M2b subset with immune 
complexes downregulates CD163 and CD206 and induces both pro and anti-inflammatory 
cytokines such as TNF-α and IL-10122. The M2c subtype is polarized with IL-10 and 
glucocorticoids and expresses high levels of CD163120. The three subsets have been associated 
with different functions including cell growth and tissue regeneration (M2a), 
immunoregulation (M2b), and clearing of apoptotic cells through efferocytosis (M2c)122-124. 
However, one must keep in mind that the M1/M2 classification is highly simplified, and in the 
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in vivo situation, macrophages are subjected to a vast array of differentiation and polarization 
stimuli. Thus, these cells display great plasticity and exist in a continuum of activation states.  
 
1.7 THE CSF-1/IL-34/CSF-1R SYSTEM 
The CSF-1R, also known as c-fms or CD115, controls the development and survival of myeloid 
linage cells, which include a broad range of cell types such as monocytes, tissue macrophages, 
osteoclasts, dendritic cells, and microglia. It is a class III receptor tyrosine kinase belonging to 
the platelet-derived growth factor family, and is activated by two ligands; the macrophage 
growth factors CSF-1 and IL-3469.  CSF-1R is comprised of an extracellular portion containing 
five immunoglobulin domains as well as a transmembrane domain, and an intracellular domain. 
The intracellular domain consists of a juxtamembrane domain (JMD) and an intracellular 
kinase domain divided by a kinase insert domain. The last component is a C-terminal domain. 
Upon binding one of its ligands, dimerization and activation of the receptor ensues with 
autophosphorylation of cytoplasmic tyrosine residues. These are used as docking sites for 
various signaling proteins such as phosphoinositol 3-kinase (PI3K), extracellular signal 
regulated kinases (ERK), Src kinases, and nuclear factor-κB (NF-κB) that regulate 
differentiation, proliferation, survival and activation of macrophages69,125 (Figure 5).  
 
 
Figure 5. Schematic illustration of the structure of CSF-1R. 
Illustration adapted from Fleetwood et al. 2016125. 
Abbreviations: CSF-1; colony-stimulating factor 1, IL-34; 
interleukin-34, JMD; juxtamembrane domain, ATP; adenosine 
triphosphate binding, KI; kinase insert, C term; C-terminal 
domain, PI3K; phosphoinositol 3-kinase, ERK; extracellular 
signal regulated kinases, Src; Src kinases, NF-ΚB; nuclear 
factor-κB.  
 
 
 
 
 
CSF-1 was the first of the CSFs to be discovered, and was shown to stimulate formation of 
macrophage colonies by murine bone marrow cells126. Although CSF-1 and IL-34 share no 
similarities in DNA sequence, IL-34 was identified in 2008 as an alternative ligand to CSF-1R, 
capable of differentiating and maintaining mononuclear phagocyte linage cells in a similar 
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fashion to CSF-1127. This important finding explained the more severe phenotype observed in 
mice lacking CSF-1R (CSF-1R -/-) compared with mice lacking CSF-1 (CSF-1op/op)128.  
Beyond binding to CSF-1R, IL-34 also interacts with two other receptors;  receptor type-
protein tyrosine phosphatase zeta and syndecan-1, implying that this cytokine may exert 
additional functions129,130. CSF-1 and IL-34 display overlapping functions however, 
differences have been found regarding their expression patterns in tissues. Studies in mice have 
demonstrated that CSF-1 is broadly expressed and crucial for the maintenance of macrophages 
and regulation of osteoclastogenesis128. IL-34 on the other hand, is reportedly high in neuronal 
tissues and skin, and important for the development of microglia and Langerhans cells131. On 
the other hand, IL-34 induces osteoclast formation and bone resorption together with RANKL 
and reduces trabecular bone mass in mice when administered systemically, suggesting that it 
also plays an important role in osteolytic processes132. While CSF-1 and IL-34 possess similar 
ability to differentiate and maintain macrophages, differences have been reported regarding 
their signal activity133. IL-34 induces a stronger tyrosine phosphorylation and downregulation 
of the CSF-1R compared to CSF-1. Furthermore, macrophages differentiated with either CSF-
1 or IL-34 also exhibit differences in their secretome, where CSF-1 induces high secretion of 
CCL2, whereas IL-34 strongly upregulates CCL11133. Boulakirba and colleagues assessed the 
secretome and potential to phagocytose bacteria by CSF-1 or IL-34 differentiated macrophages 
in response to polarization134. They found that, compared to CSF-1 derived macrophages, IL-
34 differentiated M1 and M2 macrophages secrete high levels of CCL17 and IL-10 
respectively. Furthermore, CSF-1 differentiated M2 macrophages displayed a higher capability 
of phagocytosing bacteria in comparison to IL-34 derived M2 macrophages. Moreover, the 
authors assessed the relevance of the variations in the secretome and showed that CSF-1 and 
IL-34 derived macrophages differ in their ability to polarize T-cells.  
The CSF-1/IL-34/CSF-1R system is implicated in several chronic inflammatory diseases 
exhibiting tissue destruction. Increased expression of CSF-1 and IL-34 has been reported in 
synovial fluid from RA patients135,136, as well as in inflamed RA synovial tissue together with 
increased CSF-1R expression137,138. Other studies have reported elevated levels of CSF-1 and 
IL-34 in inflammatory bowel disease, and in serum from patients with systemic lupus 
erythematosus (SLE) 139-142. Furthermore, in a study on Sjögren’s syndrome, IL-34 expression 
was found to be increased in inflamed salivary glands143.  
CSF-1 concentrations are reportedly higher in the circulation of patients with PD compared 
with controls144. Furthermore, these authors showed that PBMCs isolated from PD patients 
were able to induce osteoclastogenesis in the presence of RANKL alone, whereas PBMCs 
isolated from control individuals needed CSF-1 supplementation. These findings suggest a role 
for CSF-1 in priming PBMCs for osteoclastogenesis. Another group reported reduced 
osteoclast differentiation and alveolar bone loss in a mouse model treated with a CSF-1R 
neutralizing antibody145, further suggesting that the CSF-1/CSF-1R system may play an 
important role in inflammatory bone resorption during PD. Thus, although CSF-1R signaling 
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plays a crucial role for the development and maintenance of myeloid cells, overexpression of 
these factors during chronic inflammation may have harmful effects on host tissues.   
 
1.8 MONOCYTES AND MACROPHAGES IN PD 
Researchers have used different experimental approaches in attempt to delineate the role of 
macrophages in PD. In a mouse model of P. gingivalis induced PD, it was demonstrated that 
CD86+ M1 macrophages are the predominant phenotype in the gingival inflammatory infiltrate 
as opposed to CD206+ M2 macrophages146. Other in vitro studies have also reported a shift 
towards M1 polarization by this periodontal pathogen. Utilizing mouse macrophages, Yu and 
colleagues demonstrated that P. gingivalis induces M1 activation and inhibits the production 
of  α-ketoglutarate which is involved in M2 activation147.  
Several strategies to deplete macrophages or inhibit their activation have also been tested in 
animal models. For example, liposomes containing the bisphosphonate clodronate induces 
apoptosis in macrophages when engulfed and phagocytosed148. In animal models of PD, 
treatment with clodronate liposomes depletes gingival macrophages and reduces alveolar bone 
loss146,149. However, since macrophages are also important players in tissue regeneration and 
healing, depleting them completely may have a negative impact on host tissues. The plasticity 
and overlapping functions of macrophage phenotypes makes it challenging to target 
pathological macrophages specifically150. Thus, a more beneficial approach may be to induce 
a phenotype associated with resolution of inflammation and healing. In a mouse model of PD, 
Viniegra et al. induced a pro-resolving CD206+ macrophage phenotype using the peroxisome 
proliferator-activated receptor-γ agonist rosiglitazone, which resulted in reduced bone loss 
during PD and enhanced bone regeneration during the healing phase149. This effect was found 
to be partly mediated by the actions of M2 derived cystatin C on osteoblasts and osteoclasts.  
The importance of the chemokine CCL2 in periodontal inflammation is emphasized by the 
correlation of its levels in GCF with CAL151. Furthermore, in an experimental PD model 
utilizing rats, CCL2 was found to correlate with inflammatory cell infiltration in the gingiva as 
well as alveolar bone loss152. These findings indicate that monocytes are recruited from the 
circulation and contribute to tissue degradation in PD. Studies investigating monocyte subsets 
in humans have shown increased proportions of the intermediate and non-classical subsets in 
the circulation of PD patients153-155. However, there are also reports of unaltered proportions in 
the circulation during PD156. These conflicting results emphasize the need for more studies to 
delineate the characteristics of monocytes in the circulation of PD patients. Characterization of 
monocyte subsets has also been performed in gingiva showing elevated frequencies of 
intermediate and non-classical subsets154,157. 
Isolation and culture of monocytes from PD patients and controls have rendered interesting 
results regarding their activation state during PD. In a study by Cheng et al. P. gingivalis 
induced the activation markers CD40, CD54, and HLA-DR on monocytes. Furthermore, 
monocytes isolated from PD patients induced significantly higher IL-17 production by T cells 
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in co-culture compared with monocytes from control individuals158. In another study on whole 
blood samples, mass cytometry analysis revealed heightened TLR2/TLR4 signaling responses 
to P. gingivalis LPS by monocytes from PD patients159. Together, these findings indicate that 
peripheral blood monocytes display an activated state and are primed for inflammation in PD. 
Enhanced osteoclast activity and bone resorption are hallmarks of PD. In line with this, Herrera 
et al reported that PBMCs isolated from PD patients are primed for osteoclast differentiation 
and display high resorption activity when differentiated into osteoclasts compared with PBMCs 
from controls144. Moreover, PBMCs from PD patients exhibited elevated production of 
inflammatory mediators, including TNF-α, IL-1β and CCL2, further supporting that these cells 
display an enhanced activation state in PD. 
Increased proportions and numbers of CD68+ macrophages have been reported in PD-affected 
gingiva with correlations to collagen destruction26,160,161. Studies attempting to characterize 
macrophage phenotypes have presented varying results. Comparing typical markers used for 
identifying classical and alternative macrophages, including iNOS, CD80, CD206, and CD163, 
as well as analysis of pro- and anti-inflammatory cytokine expression have resulted in reports 
of higher proinflammatory macrophage activity in PD157,162. On the other hand, in a study by 
Garaicoa-Pazmino and colleagues, no difference in macrophage polarization was found in 
gingiva from PD patients and control individuals163.  
The role of monocytes and macrophages, as well as factors that regulate them in PD remain to 
be fully elucidated. In the studies included in this thesis we utilized human samples (gingival 
tissue, peripheral blood, saliva and isolated cells) with the aim to investigate monocyte and 
macrophage functions in PD.  
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2 AIMS OF THE THESIS 
 
The overall aim of the thesis was to investigate the involvement of monocytes and macrophages 
and factors that regulate them in periodontitis (PD). 
Specific aims: 
• To explore monocytes/macrophages as well as myeloid-related inflammatory 
mediators in clinical samples from individuals with and without PD. 
 
 
• To assess functions of monocyte-derived cells in inflammation and tissue degradation 
using oral tissue cultures. 
 
 
• To investigate the role of gingival fibroblasts regarding production of growth factors 
that regulate monocyte/macrophage function. 
 
• To explore potential strategies to dampen monocyte/macrophage mediated 
inflammatory processes.  
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3 METHODS 
 
This section will briefly describe the methods used for the experiments in this thesis.  
3.1 ETHICAL CONSIDERATIONS 
The collection of human gingival tissue samples, buffy-coated blood from anonymous donors 
(study I-IV), and peripheral blood from PD patients and controls (study II) was approved by 
the regional ethics committee in Stockholm, Sweden. The collection of saliva samples (study 
II) was approved by the regional ethics committee at Lund University, Sweden. All the studies 
were carried out in accordance with the declaration of Helsinki. A written, informed consent 
was given by all participants before inclusion in the studies. 
 
3.2 RESEARCH SUBJECTS 
For all studies, gingival tissue biopsies were harvested during planned periodontal surgery (PD-
patients) or non-periodontal surgery, e.g. surgical extractions or dental implant surgery 
(controls). The inclusion criteria for PD patients were ≥ 4 teeth with a probing depth of ≥ 6 mm 
and a persistent pocket of ≥ 6 mm at the site of biopsy collection. The inclusion criteria for the 
controls were no pockets with probing depth of ≥ 4 mm and no alveolar bone loss exceeding 
1/4 of the root length. Exclusion criteria for both groups included subjects with systemic or 
genetic diseases or antibiotic treatment in the last three months prior to oral surgery.  
Gingival tissue used for immunohistochemistry was collected in histocon and the samples were 
embedded in optimal cutting temperature compound on the collection day. Gingival tissue 
samples were collected in RNAlater for mRNA-analysis and stored in 4°C for 1-3 days. The 
RNAlater was then removed and samples stored in -80°C until RNA extraction. For western 
blot, gingival tissue samples were snap frozen using dry ice and then stored in -80°C until 
homogenization and protein extraction. Tissue to be used for flow cytometry was collected in 
complete RPMI media and stored on ice. Digestion of the tissue was performed 2-4 h after 
collection. 
For study II, a cohort of individuals living in Kalmar county, Sweden was recruited, and all 
participants answered a questionnaire regarding sex, smoking habits, and the presence of 
diseases. The participants were orally examined and provided a sample of stimulated saliva.  
Peripheral blood was obtained from PD patients and controls recruited at the student dental 
clinic at Karolinska Institutet (study II). Buffy-coated blood was obtained from anonymous 
donors at the Karolinska University hospital, Stockholm (study I, II, and IV). The blood was 
used for PBMC and monocyte isolation.  
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3.3 CELL AND TISSUE CULTURE  
3.3.1 Gingival fibroblast isolation and culture (study III) 
Gingival tissue explants used for primary GF isolation were placed in αMEM supplemented 
with fetal bovine serum (FBS), glutamine, penicillin streptomycin (pen-strep), and Antibiotic-
antimycotic after excision. Using an explant method, the biopsies were cut into small pieces 
and placed under cover glasses in 6 well plates and incubated in 37°C with 5% CO2. 
 When 
cultures of GFs were established, the gingival tissue was removed. Cells were trypsinized and 
transferred to cell culture flasks. Dulbeccos’s Modified Eagle Medium (DMEM/F12), 
supplemented with FBS, glutamine and pen-strep was added and changed every other day.  GFs 
were passaged when 80% confluent. For experiments, cells in passages 4-6 were cultured in 6 
or 12 well plates. The cells were treated with TNF-α, IL-1β, P. gingivalis or Escherichia coli 
LPS and untreated cells were used as controls. Cell lysates were collected for RNA isolation 
and mRNA analysis and supernatants were collected for analysis of protein expression with 
ELISA. GFs were also cultured on chamber slides. When 80% confluent, cells were fixed in 
ice cold acetone and subjected to immunofluorescent staining. 
 
3.3.2 Isolation and culture of PBMCs and monocytes (study I, II, and IV) 
In study I, II and IV, PBMCs were isolated from buffy-coated blood using Ficoll-Hypaque 
gradient centrifugation. The cells were used for flow cytometry analysis directly or cultured in 
complete RPMI 1640 media supplemented with different combinations of CSF-1, IL-34 or E. 
coli LPS in 37°C with 5% CO2. Cells were also incubated with a CSF-1R neutralizing antibody 
or isotype control antibody. At the end of experiments, supernatants were collected for analysis 
of cytokine secretion and cells were subjected to flow cytometry analysis.  
Monocytes were isolated from PBMCs from buffy-coated blood (study I and II) and from 
peripheral blood from PD and control donors (study II), using a monocyte enrichment kit 
without CD16 depletion. The cells were processed for mRNA expression analysis, used for 
monolayer experiments, and differentiation of macrophages. Monocytes were also 
implemented in the oral tissue cultures. Supernatants from monocytes were collected for 
measurement of various cytokines with enzyme-linked immunosorbent assay (ELISA). 
Monocytes and macrophages were further subjected to flow cytometry analysis.   
 
3.3.3 Oral mucosa tissue cultures (study I and II) 
An oral mucosa tissue culture was developed to study the interaction between monocytes, 
fibroblasts and epithelial cells. The membrane of transwell culture inserts were coated with an 
acellular collagenous layer (collagen I) and placed in 6-well plates. Next, primary GFs were 
trypsinized and suspended in complete DMEM and diluted in a collagen/DMEM suspension. 
The suspension containing GFs was then added to the acellular layer in the inserts, followed 
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by addition of 2 ml complete DMEM media to the wells after 2 h incubation in 5% CO2 at 
37°C. The models were incubated for 5-7 days letting the fibroblasts remodel the collagen. 
Media was changed every other day. Thereafter, the media in the wells was removed and 
replaced with 1.5 ml complete DMEM. Monocytes isolated from PBMCs and suspended in 50 
µl complete RPMI were added on top of the fibroblasts and incubated for 1.5 h. Next, 1,5 ml 
complete DMEM was carefully added to the inserts followed by a 24 h incubation to let the 
monocytes attach. The media was then removed from the inserts and the media in the wells 
was replaced with 1.5 ml complete DMEM. TERT-immortalized normal human oral 
keratinocytes (OKF6/TERT-2 cell line)164 were suspended in 50 µl complete keratinocyte 
serum free (K-SFM) media, added on top of the monocyte/fibroblast-layer, and incubated for 
1.5 h. Then, 2ml of K-SFM media was added to the inserts followed by a 48 h incubation. The 
models were then air-exposed by removing all media and adding 1.8 ml complete K-SFM to 
the wells, letting  the epithelium to stratify. The oral tissue cultures were air-exposed for 3-4 
days with media change every second day. The tissue cultures were subsequently subjected to 
stimulations with E. coli LPS and IFN-γ in the inserts. For experiments assessing the effect of 
COX2 inhibition, a COX2 inhibitor was added to the wells 30 min before LPS stimulation. 
Oral mucosa tissue cultures without monocytes were also stimulated with rhMMP12 in the 
inserts. Supernatants were collected for analysis of cytokine production and the oral tissue 
cultures were prepared for flow cytometry, mRNA or histological analysis. 
 
3.3.4 Gingival explant experiments (study IV) 
Gingival tissue from PD patients was collected in complete RPMI media and cut into small 
pieces using a biopsy punch and scalpel. The tissue was then incubated in complete RPMI 
media with a CSF-1R neutralizing antibody or IgG1 isotype control antibody for 72 h in a 96 
well plate. Supernatants were collected after 24 h and 72 h for protein analysis. At the end of 
the 72 h time-point, the gingival tissue was washed in PBS and placed in a protein lysis buffer 
supplemented with a protease and phosphatase inhibitor cocktail. The tissue was homogenized 
using a tissue lyser and the total protein of each tissue piece was measured with a colorimetric 
assay. MMPs in the supernatants were analyzed with a bead-based multiplex array and 
normalized to the total protein of the tissue. Gingival explants were also subjected to flow 
cytometry analysis.  
 
3.4 GENE EXPRESSION ANALYSIS 
3.4.1 RNA isolation, cDNA synthesis and quantitative real-time PCR 
RNA extraction from gingival tissue and cells was performed with different methods. The RNA 
quantity and purity were measured using a spectrophotometer and subsequently reversed 
transcribed into complementary DNA (cDNA) and used for quantitative real-time PCR (qRT-
PCR) analyses.  
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For qRT-PCR, SYBR Green with specific primers (study II, III, and IV, Table 1) or TaqMan 
gene expression assays (study I) were used. The relative mRNA expression of specific genes 
was calculated using the comparative threshold (ΔΔCt) method. First the Ct values of each 
sample was normalized to the housekeeping gene GAPDH (CT target- CT housekeeping gene 
= ΔCt). The ΔΔCt (ΔCt sample – ΔCt control average) was calculated, and fold change in 
mRNA expression calculated using the formula: 2^(-ΔΔCt).  
 
Table 1. Primer sequences used for RT-qPCR with SYBR Green. 
Gene Forward Reverse 
CD206 GGGTTGCTATCACTCTCTATGC TTTCTTGTCTGTTGCCGTAGTT 
CD64 GCATGGGAAAGCATCGCTAC GCAAGAGCAACTTTGTTTCACA 
CD68 GTCCACCTCGACCTGCTCT CACTGGGGCAGGAGAAACT 
CSF1 GTGGAACTGCCAGTGTAGAGG TGGAGGGCAGACCACATT 
CSF1R ATGCTACCACCAAGGACACA AGCCTCCTGGGTTTCTGG 
IL34 GCCACCCATCCTGGAAGTA GACAACACGGATTCCACCTT 
S100A12 CACATTCCTGTGCATTGAGG GGTGTCAAAATGCCCCTTC 
GAPDH TCCACTGGCGTCTTCACC GGCAGAGATGATGACCCTTTT 
 
In study I, a multiplex real-time PCR was used with custom primers and probes to analyze the 
mRNA expression of specific genes in gingival tissue from PD and controls. Genes analyzed 
were: TNF, COX2, CXCL11, IL10, IL1RN, IDO, MRC1, DCSIGN, PDGFD, MMP12, and 
TIMP1. GNB2L1 was used as endogenous control. Absolute quantification was performed 
using a set of purified amplicons as standards. 
 
 20 
3.5 PROTEIN EXPRESSION ANALYSIS 
3.5.1 Western blot  
Total protein was extracted from gingival tissue for protein analysis using a protein extraction 
buffer, and the tissue was homogenized using a tissue lyser. Fifteen micrograms of total protein 
per lane were loaded and separated by precast polyacrylamide gels and subsequently 
transferred to nitrocellulose membranes. The membranes were blocked with TBS-T containing 
non-fat milk powder and subsequently washed in TBS-T. Primary antibodies for MMP-12, 
S100A12, CSF-1, IL-34, and CSF-1R were incubated in 4°C overnight followed by incubation 
with secondary antibodies. The membranes were developed with a chemiluminescent solution 
and an imaging system and software were used for detection. The membranes were then 
washed, blocked and stained for β-actin which was used as loading control. For quantification 
of bands, the volume intensity of the protein of target was normalized to the loading control.  
 
3.5.2 Immunohistochemistry and immunofluorescence 
In study II, III, and IV, immunohistochemistry was utilized to analyze the expression and 
localization of inflammatory mediators and cell markers in gingival tissue. Acetone was used 
as fixative and the washing procedure was performed with PBS containing non-fat milk and 
bovine serum albumin. To block endogenous peroxidase, the tissue sections were incubated in 
methanol containing H2O2 followed by incubation with blocking buffer. Primary antibodies for 
S100A12, CSF-1, IL-34, and CSF-1R were incubated in 4°C overnight followed by incubation 
with secondary antibodies. Avidin-Biotin complex was added to the tissue sections. 
Development was performed with diaminobenzidine (DAB) solution and counterstaining with 
Mayer’s hemalum. Lastly, the sections were dehydrated with ethanol and xylene, and then 
mounted with Pertex mounting medium. A light microscope was used for development. 
Immunofluorescence was used in study I and II for double labeling of cells and analysis of 
structural proteins in gingival tissue and oral tissue cultures. Frozen sections of gingival tissue 
or oral tissue cultures were fixed using acetone or formaldehyde. Sections were incubated with 
Image It Fx signal enhancer and blocked with serum and Background Buster.  The sections 
were incubated with primary antibodies in 4°C overnight in a wet chamber. Staining was 
detected by fluorochrome-labeled secondary antibodies and cell nuclei counter staining was 
performed with DAPI. The sections were mounted with Pro Gold Antifade mounting medium. 
A fluorescence microscope or confocal microscope was used for visualization.   
 
3.5.3 Enzyme-linked immunosorbent assay (ELISA) 
In all studies, commercial ELISA kits were used to measure protein concentrations in 
supernatants from in vitro cell culture experiments or saliva. Concentrations of CSF-1, 
S100A12, TNF-α, IL-1β, IL-6, IL-8, and MMP-9 were measured with sandwich ELISA: a 
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capture antibody for the protein of interest was coated in 96-well plates and incubated overnight 
in room temperature. Next, the plates were washed to remove unbound antibodies, and 
subsequently incubated with the samples and standards. A biotinylated detection antibody that 
binds to the target protein was then added to the wells forming and antibody-antigen complex. 
Unbound antibodies were washed away and streptavidin-HRP added to the wells, binding to 
the detection antibody. The washing step was repeated followed by development with substrate 
solution. The development was stopped with 2N H2SO4 and the optical density of the wells 
was determined with a microplate spectrophotometer. Concentrations of IL-34 and MMP-12 
were measured with pre-coated sandwich ELISAs.  
 
3.5.4 Bead-based multiplex array (study IV) 
Supernatants from gingival explants were analyzed with a Bio-Plex Pro Human MMP 9-plex 
panel kit. The MMPs included in the panel were: MMP-1, -2, -3, -7, -8, -9, -10, -12, and 13. 
The fluorescently dyed magnetic beads each have a unique color code to discriminate between 
the different analytes.  Capture antibodies are covalently coupled to beads and bind the targets 
of interest. The beads were added to the wells of a microplate and washed, followed by 
incubation of standards and samples. Following washing, a detection antibody was added to 
the wells. The addition of the secondary antibody creates a sandwich complex. Next, the wells 
were incubated with streptavidin-PE which creates the final detection complex (Figure 6). The 
beads were then resuspended in assay buffer and data was acquired with a bio-plex system. 
The bio-plex uses two lasers during data acquisition; one for bead-classification and one to 
excite the PE to generate a reporter signal. 
 
 
Figure 6. Schematic illustration of a bio-plex sandwich complex used in the bead based multiplex array. 
Illustration by Reuben Clark  
 
3.5.5 Flow cytometry (study I, II, and IV) 
Analysis of the cell surface and intracellular protein expression of individual cells in digested 
gingiva or cells isolated from blood was performed with flow cytometry.  
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Flow cytometry works by labeling cells in a suspension with fluorochrome-conjugated 
antibodies targeting specific cell components. When labeled cells are passaged in a single file 
through the flow cytometer, the fluorochromes are excited by lasers and emit light at different 
wavelengths. The emitted light is passed through optical filters and measured by detectors. 
Thus, if light of a certain wavelength is detected, it means that the cell was labeled with a 
specific fluorochrome-conjugated antibody. Determination of the size and granularity of cells 
is performed by measuring forward and side scattering of light.  
Gingival tissue harvested during surgery was cut into small pieces and enzymatically digested 
with Dnase I and collagenase II. After digestion, the suspension was filtered through a mesh 
filter and centrifuged. First, the cells were subjected to viability stain followed by Fc block. 
The cells were then incubated with different combinations of fluorochrome-conjugated 
antibodies on ice. Next, the cells were fixed and analyzed, or permeabilized and stained with 
intracellular antibodies. The samples were analyzed with a flow cytometer and data processed 
with FlowJo software.  
 
3.6 STATISTICAL ANALYSIS 
Data analysis was performed with GraphPad prism or SPSS statistical software. The statistical 
methods used in the studies are briefly outlined below. Detailed descriptions of the statistical 
methods used for each experiment are provided in the studies. 
In study I, Mann-Whitney U test or unpaired t-test was applied when appropriate for 
comparison of two groups. Friedman test with Dunn’s multiple comparisons test was used to 
compare three groups or more.  
In study II, Mann-Whitney U test or Wilcoxon was used for comparison of two groups. For 
comparison of three groups or more, Friedman test with Dunn’s multiple comparisons test, or 
Kruskal-Wallis-test with Dunn’s multiple comparisons test was applied. Spearman rank 
correlation coefficient was applied to analyze correlations. 
In study III, Mann-Whitney U test was applied to compare protein expression in gingival tissue 
and mRNA expression in GFs. Kruskal-Wallis test with Dunn’s multiple comparisons test was 
used for comparison of ELISA data. 
In study IV, Mann-Whitney U test or paired t test was applied to compare two groups. One-
way or two-way ANOVA with Sidak’s multiple comparisons test was used when appropriate 
to compare three groups or more. 
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4 RESULTS AND DISCUSSION 
 
The following section will give an overview of the results in this thesis. 
 
4.1 STUDY I 
4.1.1 MMP-12 expression in gingival tissue 
To assess genes related to myeloid cell functions in gingival tissue from PD patients and 
controls, a mRNA multiplex array was utilized. This revealed an up-regulation of MMP12, 
COX2, TNF, and dendritic cell specific intercellular adhesion molecule-3 grabbing non-
integrin in PD. Several MMPs are elevated in PD, and they have been proposed to be potential 
biomarkers for the disease53,165. Therefore, MMP-12 protein expression was further analyzed 
in gingival tissue using western blot, which revealed elevated MMP-12 in PD-affected gingiva. 
In a later study by our group, salivary levels of MMP-12 were reported to be associated with 
periodontal inflammation68, further suggesting its involvement in PD.  
In vitro experiments have shown that MMP-12 contains a potent ability to degrade the elastin 
precursor tropoelastin56. Interestingly, the expression of tropoelastin was significantly lower in 
gingival tissue from PD patients, suggesting that MMPs targeting elastin, such as MMP-12, are 
involved in undermining the oral mucosa during inflammation. RA is another chronic 
inflammatory disease exhibiting tissue degradation, and previous findings have demonstrated 
that MMP-12 is elevated in the synovium during RA and expressed by macrophages55. In 
consonance with this, we found that the expression of MMP-12 was primarily associated with 
CD68+ cells at inflamed sites in gingival tissue. Flow cytometry analysis of digested gingival 
tissue further revealed that the increased expression of MMP-12 in PD was attributed to a 
CD68+CD14+CD64+ cell population, likely to be monocyte-derived cells. These cells displayed 
low surface molecule expression of the co-inhibitory receptor CD200R. This is interesting 
considering that low CD200R expression on monocytes and macrophages has been found in 
other inflammatory diseases, such as RA and sarcoidosis, and is associated with an enhanced 
inflammatory state166,167.  
 
4.1.2 Oral tissue cultures to study monocyte-derived cells 
Co-culture systems provide the opportunity to study cellular functions in a setting resembling 
the tissue environment. We developed an organotypic three-dimensional oral tissue culture 
consisting of primary gingival fibroblasts embedded in collagen I, monocytes isolated from 
PBMCs, and the oral keratinocyte cell line, OKF6/TERT-2164. This system allowed us to study 
the function of monocyte-derived cells during oral tissue inflammation. Histologically, the oral 
tissue cultures with implanted monocytes resembled normal gingival tissue morphology with 
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a stratified epithelium on top of the fibroblasts/collagen matrix (Figure 7). The models also 
displayed a similar expression pattern of structural proteins as seen in normal gingival tissue.  
 
Figure 7. Hematoxylin and eosin staining showing morphology of A) Oral mucosa tissue culture. B) Normal 
gingival tissue. The morphology of the oral mucosa tissue cultures resembles that of normal gingival tissue, with 
a stratified squamous epithelium and a basement membrane separating the epithelium from the underlying 
connective tissue. Scale bars 50µm. 20x magnification. Photos by Reuben Clark. 
A constitutive production of CSF-1 along with up-regulation of the markers CD14, CD68 and 
CD163 over time indicated that the model promoted monocyte survival and macrophage 
differentiation. Classical macrophage activation with LPS and IFN-γ has been reported to 
upregulate the expression of CD80 and downregulate CD200R in monocultured 
macrophages168. In line with this, LPS/IFN-γ stimulation induced inflammation in the tissue 
cultures, resulting in upregulation of CD80 and CD14 expression and downregulation of 
CD200R on monocyte-derived cells. The downregulation of CD200R is in line with the 
phenotype of monocyte-derived cells we observed in PD-affected gingiva.  
Utilizing multiplex real-time PCR, we analyzed the expression of genes associated with 
monocyte/macrophage function in oral tissue cultures with and without monocytes. LPS/IFN-
γ stimulation in cultures with monocytes induced an inflammatory profile with significantly 
increased mRNA expression of MMP12, TNF and COX2 compared with unstimulated cultures, 
thus resembling the gene expression profile of inflamed gingival tissue. In contrast, tissue 
cultures without monocytes exhibited low expression of these markers and the expression was 
not induced in response to inflammatory stimulation. This demonstrates the importance of 
monocytes in inducing an inflammatory gene expression profile in the oral tissue cultures in 
response to proinflammatory stimuli. This was further confirmed with ELISA demonstrating 
the need for monocytes for the secretion of MMP-12 and TNF-α. Co-culture experiments have 
shown that GFs maintain both lymphocyte and monocyte populations and that the interaction 
between fibroblasts and PBMCs induce proinflammatory cytokine production80,169. Another 
study reported enhanced production of MMP-3 and MMP-9 in response to LPS stimulation in 
co-cultures of GFs and macrophages170. Thus, the crosstalk between non-immune cells and 
monocyte-derived cells is important for a wide array of functions and studying these cells in 
co-culture systems may reveal functions otherwise missed in a monoculture setting. In line with 
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the previously found effect of MMP-12 on matrix components56,171, we found that stimulating 
the oral mucosa with recombinant MMP-12 resulted in detachment of the epithelium from the 
fibroblast matrix, and lower tropoelastin and fibronectin expression in the oral mucosa tissue 
cultures, thereby adding to the notion that MMP-12 plays a role in degrading the oral mucosa. 
 
4.1.3 Modulation of the CD200/CD200R pathway in monocyte-derived cells 
Oral tissue cultures and monocytes cultured in monolayer were used to investigate the 
inflammatory pathways regulating MMP-12 production.  The  cyclooxygenase (COX)-
2/prostaglandin E2 (PGE2) pathway has previously been reported to be an important regulator 
of MMP expression in macrophages172.  In the presence of LPS and a COX2 inhibitor, the 
PGE2 production was attenuated. However, the production of MMP-12 remained unaffected, 
leading to the conclusion that MMP-12 production is not mediated via the COX2 pathway. 
CSF-2 is elevated in PD73, and we found increased CSF2 gene expression in the oral mucosa 
tissue cultures containing monocyte-derived cells when inducing inflammation using IFN-γ 
and LPS. Previous studies have demonstrated that CSF-2 stimulation induces MMP-12 
production by monocytes173, and in line with this, we observed induced MMP-12 production 
by monocyte-derived in response to CSF-2 stimulation. 
CD200 is an important regulator of monocytes and macrophages through interaction with 
CD200R174. Moreover, CD200 has been shown to inhibit the RANKL signaling pathway as 
well as osteoclast maturation175, which may have implications in osteolytic diseases such as 
PD. The low expression of CD200R on monocyte-derived cells in PD could possibly lead to 
an enhanced inflammatory state due to the lack of CD200 mediated inhibition, with elevated 
MMP-12 production as a result. In support of this, addition of a CD200 Fc chimera significantly 
reduced the MMP-12 production by monocyte-derived cells. Taken together, these results 
suggest that MMP-12 produced by monocyte-derived cells is involved in the tissue-degrading 
events during PD, and that the CD200/CD200R pathway is a potential target to reduce the 
impact of MMP-12 on host tissues. 
 
4.2 STUDY II 
4.2.1 S100A12 expression in gingival tissue and saliva 
S100A12 belongs to the S100 family of calcium binding proteins and plays an important part 
in the initiation of innate immune responses by acting as a pro-inflammatory alarmin176. We 
aimed to assess the expression of this protein in samples from subjects with and without PD. 
In gingiva, histological assessment revealed abundant S100A12 staining in proximity to the 
inflammatory infiltrate in the connective tissue, and western blot analysis demonstrated 
increased S100A12 protein in PD gingiva compared with controls. Elevated levels of S100A12 
have been detected in serum and synovial tissue from RA patients as well as in fecal samples 
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from IBD patients, suggesting that this protein potentially could be utilized as a biomarker of 
inflammation67,177. In a large cohort of orally examined participants, we found that the salivary 
levels of S100A12 were increased with BOP and presence of gingival pockets. Furthermore, 
S100A12 was significantly higher in patients with severe stages (III and IV) of PD compared 
with periodontally healthy participants and individuals with gingivitis. Individuals with PD 
stages I and II showed a tendency towards increased S100A12 compared with the 
healthy/gingivitis group. These results are supported by a previous study conducted by our 
group, showing that salivary levels of S100A12 correlate with the severity of periodontal 
inflammation68. Besides being regulated in saliva, S100A12 is also elevated in serum and GCF 
from PD patients and correlates with the expression of C-reactive protein178. Together, these 
findings suggest that S100A12 is a potential biomarker for PD. Whether or not it could be 
targeted as a therapeutic measure remains to be elucidated. However, it has been proposed as 
a potential target for inflammatory osteolysis due to its capacity to differentiate monocytes into 
osteoclasts and enhance their bone resorption ability179.  
 
4.2.2 Expression of S100A12 in monocytes and during macrophage 
differentiation 
We aimed to assess the expression of S100A12 in monocyte subsets as well as during 
macrophage differentiation and polarization. For this we used PBMCs from buffy-coated blood 
and isolated monocytes using a monocyte enrichment kit. Flow cytometry was used to identify 
the subsets with a gating based on CD14 and CD16 expression. According to previous results 
in peripheral blood, the frequency of classical monocytes was around 85%, intermediate 
monocytes approximately 7%, and the non-classical subset around 8%95,180. Classical 
monocytes displayed the highest proportion of S100A12+ cells and also had the highest 
expression as measured by median fluorescence intensity, whereas non-classical monocytes 
displayed the lowest expression and frequency of S100A12+ cells, which is in line with 
previous findings95,181. Intermediate monocytes expressed S100A12 at levels between the 
classical and non-classical subset but had a more similar expression to classical monocytes. 
Classical monocytes are potent responders to bacterial stimuli95,97, and the high expression of 
S100A12 by this subset further suggests that S100A12 is involved in supporting 
inflammation182. 
The gene expression of S100A12 significantly decreased during macrophage differentiation in 
response to CSF-1 which is also in accordance with previous reports183. In our study, we found 
that the secretion of S100A12 decreases during macrophage differentiation, and thereby 
follows the gene expression pattern. The decreased expression of S100A12 in non-classical 
monocytes and during macrophage differentiation is in line with the notion that monocytes are 
believed to undergo maturation from classical monocytes, to intermediate and lastly the non-
classical subset93. CSF-1-differentiated macrophages were polarized into classically activated 
macrophages using LPS and IFN-γ, or alternatively activated macrophages with IL-4 and IL-
13. Similar to the results by Shah et al.183, the S100A12 gene expression was unaltered with 
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macrophage polarization. Moreover, we found that S100A12 secretion by macrophages 
remained unaltered with polarization. Oral tissue cultures were prepared either with or without 
monocytes to assess the contribution of monocyte-derived cells to S100A12 secretion. In oral 
tissue cultures with monocytes, the S100A12 production was significantly increased over time 
and in response to LPS/IFN-γ stimulation. In contrast, the tissue cultures without monocytes 
produced low levels of S100A12 and did not respond to inflammatory stimulation, suggesting 
that the presence of monocytes is crucial for S100A12 production. We then stimulated 
monocytes with media from tissue cultures without monocytes to assess whether factors 
secreted by GFs and epithelial cells influence the S100A12 production. No apparent difference 
in S100A12 secretion was observed in response to media from unstimulated and IFN-γ/LPS 
stimulated cultures without monocytes. Thus, direct cell-cell interactions between monocytes 
and GFs/epithelial cells may play an important role for the production of S100A12 in the oral 
tissue cultures.  
 
4.2.3 S100A12 expression in peripheral blood monocytes and gingival 
macrophages during PD 
Next, we sought to analyze the characteristics of monocytes in the circulation during PD. 
Peripheral blood was obtained from PD patients and controls to assess possible differences in 
monocyte subsets and their expression of S100A12. No significant difference in monocyte 
counts was observed comparing patients and controls. Flow cytometry was used to analyze the 
monocyte subsets, revealing lower frequencies of non-classical monocytes in PD. This is a 
conflicting result to what other studies have reported, showing increased proportions of 
intermediate and non-classical monocytes in the circulation of PD patients154,157. On the other 
hand, one study reported no differences in the frequencies of monocyte subsets in circulation 
during PD156. A possible explanation for these conflicting results could be variations in the 
patient groups analyzed, such as genetic and lifestyle factors, and severity of PD. Non-classical 
and intermediate monocytes are increased in peripheral blood in several chronic inflammatory 
diseases, such as Crohn’s disease and RA184,185, which supports the notion that these subsets 
are expanded in the circulation during inflammation. One could speculate that the reported 
increased proportion of non-classical and intermediate monocytes in the circulation during PD 
could in part be explained by the migration of classical monocytes into the tissues. Another 
speculation is that leakage of periodontal pathogens into the circulation upregulates 
inflammatory mediators and enhances the activation and differentiation state of monocytes in 
the circulation  
We proceeded to assess the S100A12 expression in monocytes from PD patients and controls. 
Interestingly, higher proportions of S100A12+ monocytes were observed in PD. In consonance 
with this, monocytes from PD patients exhibited higher secretion of S100A12 when cultured 
for 24 h in vitro. This is in line with the fact that circulating monocytes have been shown to be 
primed for inflammation in PD patients, displaying several features indicating that they are 
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more responsive to bacterial/LPS stimuli159. The most prominent difference in S100A12 
expression was found in the intermediate followed by non-classical monocytes. 
We did not investigate the proportions of monocyte subsets in gingival tissue, however it has 
been reported that intermediate and non-classical monocytes are increased in PD gingival 
tissue154,157. Since these subsets represent a later maturation state, an explanation for their 
reported increase in inflamed gingival tissue could be that migrated classical monocytes 
undergo differentiation in response to CSFs and other factors in the tissue. We assessed the 
S100A12 expression in macrophage populations in gingival tissue based on the markers CD14 
and CD64. Interestingly, the proportion of S100A12+ macrophages was increased in PD-
affected gingival tissue. Furthermore, the S100A12+ macrophages in PD were less frequently 
positive for CD206. Since studies in mice have shown that expression of CD206 is associated 
with the healing phase of PD149, this may suggest that S100A12+ macrophages play a role in 
the tissue destructive processes during periodontal inflammation. 
Taken together, the notion that monocytes are important for the production of S100A12 in the 
oral tissue cultures, and that monocytes and macrophages display enhanced S100A12 
expression in PD, suggests that they are in part responsible for the abundant expression of 
S100A12 in PD-affected gingival tissue. However, in this study we did not investigate other 
immune cell populations, and S100A12 is abundantly produced by neutrophils as well182. Thus, 
expanding the oral tissue culture experiments to include other immune cell populations would 
further delineate the expression and function of S100A12 in oral tissue inflammation. 
 
4.3 STUDY III 
4.3.1 CSF-1 and IL-34 expression in gingival tissue 
The macrophage growth factors CSF-1 and IL-34 are crucial for the proliferation, 
differentiation, and survival of myeloid cells but may contribute to tissue degradation in chronic 
inflammation70. To assess and quantify the expression of CSF-1 and IL-34 in gingiva, samples 
were collected from PD patients and controls. The tissue was homogenized and subjected to 
western blot analysis. The results revealed elevated levels of CSF-1 in PD gingiva whereas IL-
34 levels displayed similar levels in the two groups. In a previous study from our group, 
elevated CSF-1 but decreased IL-34 salivary levels were found in PD71. In that study, CSF-1 
was also found to correlate with MMP-8, and both CSF-1 and MMP-8 correlated negatively 
with IL-34. CSF-1 expression may have clinical relevance as its levels in saliva are significantly 
associated with the percentage of probing depths ≤ 4 mm72. Furthermore, CSF-1 has been 
shown to be increased in the circulation of PD patients and possibly prime PBMCs for 
osteoclast differentiation144. The finding that CSF-1 but not IL-34 is upregulated in PD-affected 
gingiva adds to the notion that CSF-1 and IL-34 may be differentially regulated during 
periodontal inflammation. However, of note, increased IL-34 levels have been reported in GCF 
from PD patients186. The authors did not investigate the expression of CSF-1, and thus more 
studies are needed to compare the expression of these two cytokines in GCF. A possible 
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differential expression could in part be explained by different tissue expression patterns. In 
mice, it has been shown that CSF-1 is broadly expressed in many tissues whereas IL-34 seems 
to play a crucial role in some specific tissue types e.g. neuronal tissue and skin131,187. On the 
other hand, elevated IL-34 expression has been shown in several chronic inflammatory diseases 
such as RA, IBD and Sjögren’s syndrome, indicating a role for this cytokine in inflammatory 
processes139,143,188. To further assess the expression of these growth factors in gingiva, we used 
immunohistochemistry to stain gingival tissue from PD patients which revealed expression 
CSF-1 and IL-34 in the connective tissue. The abundance of fibroblasts in the connective tissue 
led us to hypothesize that these cells are important sources of CSF-1 and IL-34. 
 
4.3.2 CSF-1 and IL-34 expression by gingival fibroblasts 
GFs are the most abundant cells in the gingiva, and it has been shown that they play an 
important part in orchestrating the immune response75. TNF-α and IL-1β stimulation activates 
the NF-ΚB and MAPK c-jun terminal kinase (JNK) signaling pathways in GFs189,190. In a 
previous study from our group, IL-34 gene expression was found to be upregulated in GFs by 
TNF-α via the NF-kB and JNK pathways, and through the NF-kB pathway by IL-1β 
stimulation. TNF-α and IL-1β induced CSF-1 expression was regulated through NF-kB78.   
In study III we wanted to follow up on these results and assess the protein secretion of CSF-1 
and IL-34 by GFs under inflammatory and non-inflammatory conditions. The expression of 
CSF-1 and IL-34 in GFs was confirmed with immunofluorescence stainings of cells cultures 
in chamber slides. Stimulations with TNF-α, IL-1β, E. coli, or P. gingivalis LPS significantly 
increased the secretion of CSF-1 by GFs whereas only E. coli LPS significantly elevated IL-
34 production. Considering that GFs isolated from PD-affected gingiva have been shown to 
exhibit an altered inflammatory profile in vitro86,191, we hypothesized that CSF-1 and IL-34 
expression and secretion are altered in GFs isolated from PD patients. CSF-1 and IL-34 mRNA 
did not differ between patient and control GFs, however, both cytokines were constitutively 
secreted over time with higher CSF-1 concentrations measured. Proinflammatory stimuli 
increased the secretion of CSF-1 and IL-34, however no difference was observed between 
patients and controls. We did not assess the effect of LPS stimulation on CSF-1 and IL-34 
secretion which, in hindsight, would have been interesting considering the reported differential 
cytokine secretion by control and PD GFs in response to P. gingivalis LPS86,87. El-Awady and 
colleagues reported that PDLFs isolated from PD-affected teeth and cultured in vitro sustain 
their inflammatory profile without inflammatory stimuli84. In another study, Baek et al. 
reported an enhanced inflammatory state in GFs isolated from inflamed gingiva191. One 
important difference between these studies and ours is the age of the study participants, which 
in our study was quite high. Age impacts the function and characteristics of GFs192, thus a 
different result regarding CSF-1 and IL-34 expression may be observed with cells isolated from 
younger individuals.  
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4.4 STUDY IV 
4.4.1 CSF-1R expression in gingival tissue 
The finding of increased CSF-1 in PD-affected gingiva prompted us to also investigate 
expression of the receptor. Binding of CSF-1 to CSF-1R induces receptor dimerization, 
activation, and autophosphorylation of cytoplasmic tyrosine residues69. This is followed by 
regulated intramembrane proteolysis resulting in release of the cytoplasmic domain into the 
cytosol. The activated cytoplasmic domain then moves to the nucleus and regulates gene 
transcription193. To analyze the gene expression of CSF-1R we used qPCR which revealed 
similar levels in gingival tissue from PD patients and controls. We then went on to analyze the 
protein expression in homogenized gingival tissue with western blot and found significantly 
higher levels of the cytoplasmic domain of the receptor in PD. An insignificant increase in the 
expression of a 140 kDa band was observed in PD samples, likely to be the CSF-1R precursor. 
A band was also seen in close proximity to the 140 kDa band (around 150 kDa). Whether or 
not this represents the CSF-1R is difficult to establish since the expected band size of the 
receptor is 175 kDa. To complement the western blot analysis, immunohistochemistry was 
performed showing abundant CSF-1R staining in the inflammatory infiltrate in the connective 
tissue. The number of DAB+ cells/mm2 was significantly higher in PD gingival tissue compared 
with controls. To the best of our knowledge, no other studies have investigated the expression 
of CSF-1R in human gingival tissue. In contrast, more work has been conducted in the RA 
field, showing increased CSF-1R expression in inflamed synovial tissue in conjunction with 
CD68+ macrophages138, suggesting that CSF-1R takes part in regulating macrophage functions 
during tissue inflammation. 
Based on the results of elevated CSF-1R expression in gingiva, we aimed to assess the 
expression of the receptor in macrophages using flow cytometry and observed similar levels 
on cells from PD and controls. Furthermore, we assessed whether the CSF-1R expression could 
be attributed to an alternatively activated phenotype by assessing the receptor expression on 
CD206+ and CD206- macrophages, however no differences between the two populations were 
found, either in PD or controls. 
 
4.4.2 Assessment of macrophage markers in gingival tissue 
The number of macrophages in PD-affected gingiva has been investigated in several 
histological studies based on markers such as CD68, showing that macrophage counts are 
increased in PD and that their presence correlates with collagen degradation26,160. Utilizing 
qPCR, we found increased gene expression of CD68 and CD64 in PD gingiva (Figure 8). The 
proportions of macrophages in gingiva from PD patients and controls were analyzed with flow 
cytometry based on the markers CD45, HLA-DR, and CD64. The proportions of macrophages 
was unaltered in PD-affected gingiva which is in line with previous findings15. This is also in 
accordance with the results in study I and II.  
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Figure 8. Relative mRNA expression of the macrophage markers A) CD68 and B) CD64 was assessed with qPCR 
in gingival tissue from PD patients (n=6) and controls (n=6). Mann-Whitney U test was applied to determine 
statistical significance. *p<0.05, **p<0.01.  
 
We found a slightly increased CD206 mRNA expression in PD-affected gingival tissue and 
unaltered proportions of CD206+ macrophages comparing PD and controls. In PD, an enhanced 
M1/M2 ratio has been reported based on the expression of iNOS and CD206 on 
macrophages162. In that study, the absolute number of CD206+ cells was unaltered in PD 
compared with control gingiva whereas the iNOS expressing cells were elevated. On the other 
hand, another study using immunofluorescence to quantify polarized macrophages reported 
unaltered polarization in PD163. Moreover, the authors found that macrophage numbers were 
higher in gingivitis compared with PD lesions, a finding also supported by others194. An 
explanation for this could be a failure of macrophage recruitment and activation in PD195. 
Another reason for the varying results could be that the complex chronic inflammatory milieu 
during PD may harbor macrophage phenotypes involved in both proinflammatory processes 
and resolution of inflammation concomitantly. Moreover, variations in experimental 
approaches to analyze macrophage phenotypes, as well as sample sizes and donor variations in 
the groups analyzed may also affect the phenotype-profile.  
 
4.4.3 CSF-1R inhibition in PBMCs 
To assess the expression of CSF-1R on monocytes, PBMCs from buffy-coated blood were 
analyzed using flow cytometry. This confirmed previous reports that CSF-1R is primarily 
expressed by monocytes among immune cell populations in peripheral blood. Non-classical 
monocytes displayed the highest CSF-1R expression among the subsets followed by the 
intermediate subset, and lastly the classical monocytes.  
After culturing PBMCs in vitro for 24 h together with CSF-1, the intermediate monocyte subset 
predominated. CSF-1R signaling is crucial for the survival of non-classical and intermediate 
monocytes. This has been shown by the depletion of these subsets in the peripheral blood of 
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RA patients after treatment with a CSF-1 neutralizing antibody110. We aimed to assess whether 
CSF-1R blockade has an impact on the composition of monocyte subsets in cultures of PBMCs. 
Addition of a CSF-1R neutralizing antibody reduced the proportions of CSF-1R+ monocytes 
significantly and resulted in a tendency towards reduced surface expression of CSF-1R but did 
not affect the proportions of monocyte subsets. A concern regarding CSF-1R inhibition is the 
possibility of mainly targeting macrophages involved in resolution and tissue remodeling. 
Indeed, CSF-1 has been shown to polarize macrophages towards and alternatively activated 
phenotype196, and likewise, CSF-1R inhibition may in some settings reduce alternatively 
activated macrophages in tissue197. However, in another study on neuropathic pain conducted 
in mice, CSF-1R inhibition was found to mainly target classically activated CD86+ 
macrophages198. The surface markers CD163 and CD206 are associated with alternative 
activation and are downregulated in response to LPS/IFN-γ stimulation in vitro, whereas CD64 
has been shown to be upregulated116. To assess whether CSF-1R inhibition has an impact on 
these markers, we analyzed the expression of CD64, CD163 and CD206 on monocytes after 
culturing PBMCs for 24 h together with a CSF-1R neutralizing antibody and CSF-1. However, 
no difference was observed comparing cells subjected to CSF-1R blocking and IgG1/untreated 
controls. 
We hypothesized that the CSF-1/CSF-1R axis takes part in regulating the production of 
inflammatory mediators in PBMCs. Therefore, we analyzed the concentration of a number of 
inflammatory mediators known to be regulated in PD in supernatants from PBMCs subjected 
to CSF-1R inhibition. A significant reduction in IL-8 and MMP-9 levels was observed after 
receptor inhibition. In line with this, reduced production of IL-8 and MMP-9 has been reported 
in response to CSF-1R inhibition in RA synovial explants137. We then stimulated PBMCs with 
E. coli LPS which led to a predominance of the classical monocyte subset. This effect could be 
due to a reduction of CD16 in response to LPS stimulation, and the use of more stable markers 
such as CD38 have been proposed to track activated non-classical monocytes199. To further 
assess phenotypical changes of monocytes after 24 h in culture with LPS, we analyzed the 
expression of CD64, CD163 and CD206. LPS stimulation resulted in a small increase of CD64 
and a slight decrease of CD163 and CD206 expression (Fig 4C-E), however this did not reach 
statistical significance. The insignificant changes in the expression of these markers could be 
due to the lack of IFN-γ stimulation (commonly used for classical polarization in combination 
with LPS). Furthermore, we used a short incubation time of 24 h. A longer incubation of three 
to eight days to allow for macrophage differentiation may have rendered different results 
regarding the expression of these markers. 
 
4.4.4 CSF-1R inhibition in gingival tissue explants 
MMPs are key players in tissue degradation during PD. Therefore, we aimed to investigate 
their secretion after CSF-1R inhibition in gingival tissue. Two different concentrations of 
blocking antibody were tested, 0.1 µg/ml and 1 µg/ml. Addition of the lower concentration 
clearly had an impact on MMP production with significant reduction of MMP-1, MMP-12 and 
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MMP-13 compared with the isotype controls. Treatment with the higher concentration did not 
result in the same attenuation of MMPs. It would have been desirable to assess the viability of 
the cells after CSF-1R inhibition in explants to assess whether this could be attributed to toxic 
effects, however this was not performed. Moreover, in the study by Garcia and colleagues, 
blocking CSF-1 and IL-34 individually did not result in changes in the expression of 
proinflammatory mediators in RA synovial explants, which may be due to the redundant role 
of these growth factors in maintaining macrophage populations137. If the same applies for PD 
gingival explants remains to be elucidated.  
Few studies have investigated the effect of CSF-1R inhibition in PD. In a murine model, 
Kimura et al. reported that CSF-1R inhibition with a monoclonal antibody reduced 
osteoclastogenesis and RANK expression with diminished bone resorption as a result145. More 
studies have been conducted in models of other inflammatory diseases. Using a monoclonal 
antibody against CSF-1R, Toh et al. reported, depletion of osteoclasts, reduced infiltration of 
macrophages, and bone and cartilage protecting effects in animal models of RA138. 
Furthermore, anti-CSF-1R treatment had protective effects against tissue destructive processes 
in experimental models of retinal inflammation and SLE200,201. Taken together, CSF-1R may 
be a potential target to reduce destructive inflammatory processes, however more studies are 
needed to elucidate changes in macrophage functions and phenotypes in response to CSF-1R 
inhibition during periodontal inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34 
4.5 MAIN FINDINGS 
Periodontitis (PD) is a highly prevalent chronic inflammatory disease characterized by the 
destruction of tissues supporting the teeth. Monocytes and macrophages are key players in 
chronic inflammatory tissue destruction. Studying their characteristics and functions in PD is 
important to delineate possible strategies to modulate their function. 
The main findings of this thesis: 
• MMP-12 is increased in gingival tissue from PD patients and is primarily expressed by 
monocyte-derived cells. These cells exhibit low surface expresssion of the co-inhibitory 
receptor CD200R. CSF-2 induced MMP-12 is regulated by the CD200/CD200R 
pathway. Oral mucosa tissue cultures can be utilized to study monocyte-derived cells 
in a miliue that mimics inflamed oral mucosa.  
 
• S100A12 expression is increased in peripheral blood monocytes and macrophages from 
PD patients. The secretion of S100A12 by monocytes decreases during monocyte 
maturation. S100A12 is elevated in gingival tissue and reflects PD severity in saliva, 
and its production is dependent on the presence of monocytes in oral tissue cultures.  
 
• CSF-1 is increased in gingival tissue from PD patients. GFs constitutively produce 
CSF-1 and IL-34 and enhance the secretion in response to inflammatory stimuli. GFs 
isolated from PD-affected gingival tissue and controls do not differ in regards to CSF-
1 and IL-34 expression and production.  
 
• CSF-1R expression is increased in gingival tissue from PD patients but unaltered in 
macrophages from PD and control gingiva. CSF-1R inhibition attenuates inflammatory 
mediator production by PD gingival tissue explants and PBMCs.  
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